← Back to Screener
OnKure Therapeutics, Inc. Class A Common Stock (OKUR)
Price$4.99
Favorite Metrics
Price vs S&P 500 (26W)55.19%
Price vs S&P 500 (4W)9.84%
Market Capitalization$68.37M
All Metrics
Book Value / Share (Quarterly)$4.11
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.79
Price vs S&P 500 (YTD)68.28%
EPS (TTM)$-4.40
10-Day Avg Trading Volume0.19M
EPS Excl Extra (TTM)$-4.40
EPS (Annual)$-4.40
ROI (Annual)-105.93%
Cash / Share (Quarterly)$4.32
ROA (Last FY)-95.81%
EBITD / Share (TTM)$-4.62
ROE (5Y Avg)-64.60%
Cash Flow / Share (Annual)$-3.79
P/B Ratio1.22x
P/B Ratio (Quarterly)0.70x
Net Income / Employee (Annual)$-1
ROA (TTM)-74.19%
EPS Incl Extra (Annual)$-4.40
Current Ratio (Annual)10.28x
Quick Ratio (Quarterly)9.97x
3-Month Avg Trading Volume0.23M
52-Week Price Return70.65%
Revenue / Employee (TTM)$0
52-Week High$5.06
EPS Excl Extra (Annual)$-4.40
CapEx CAGR (5Y)18.13%
26-Week Price Return63.93%
Quick Ratio (Annual)9.97x
13-Week Price Return56.74%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.28x
Enterprise Value$9.318
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.32
3-Month Return Std Dev78.11%
Net Income / Employee (TTM)$-1
ROE (Last FY)-105.93%
EPS Basic Excl Extra (Annual)$-4.40
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.40
ROI (TTM)-81.69%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)35.55%
Year-to-Date Return72.41%
5-Day Price Return12.36%
EPS Normalized (Annual)$-4.40
ROA (5Y Avg)-57.50%
Month-to-Date Return20.77%
EBITD / Share (Annual)$-4.62
ROI (5Y Avg)-64.60%
EPS Basic Excl Extra (TTM)$-4.40
P/B Ratio (Annual)0.70x
Book Value / Share (Annual)$4.11
Price vs S&P 500 (13W)53.87%
Beta0.29x
Revenue / Share (TTM)$0.00
ROE (TTM)-81.69%
52-Week Low$1.70
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
OKUROnKure Therapeutics, Inc. Class A Common Stock | — | — | — | — | $4.99 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.71 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.93x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing precision cancer medicines that target biologically validated disease drivers in underserved indications. The company focuses on oncology areas with limited existing treatment options.